Distribution characteristics and associated factors of dyslipidemia across clinical stages of breast cancer: a retrospective observational study
Frontiers in Global Women's Health · 02.07.2026 · 7
DOI: 10.3389/fgwh.2026.1845647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Global Women's Health, online erschienen am 02.07.2026. Verfasst von Zechang Xin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University, Dalian, China. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Dyslipidemia is a prevalent metabolic disorder in breast cancer patients and an important comorbidity that impacts cardiovascular outcomes, treatment tolerance, and long-term prognosis. It may also be linked to tumor progression, yet the distribution characteristics of lipid abnormalities, especially their heterogeneity across different clinical stages and molecular subtypes of breast cancer, remain insufficiently characterized in existing research.
Methods
This retrospective observational study was conducted at the Affiliated Zhongshan Hospital of Dalian University, enrolling 5,246 patients with pathologically confirmed primary breast cancer diagnosed from 2014 to 2024 with complete clinical staging and fasting lipid profile data. Dyslipidemia was defined as at least one abnormal lipid parameter (LDL-C ≥ 3.4 mmol/L, HDL-C < 1.0 mmol/L, TC ≥ 5.2 mmol/L, TG ≥ 1.7 mmol/L). Stage-stratified multivariable logistic regression analyses were used to identify independent associated factors, with subtype-based subgroup analyses and sensitivity analyses excluding CHD patients performed to verify result robustness.
Results
Dyslipidemia affected 54.8%–71.9% of patients across all clinical stages, with TC and TG abnormalities being the most common, followed by reduced HDL-C and elevated LDL-C. Cumulative proportions of individual lipid abnormalities exceeded 100% per stage, indicating frequent coexistence of multiple abnormalities. Obvious subtype heterogeneity was observed: Luminal B (HER–) had low early-stage HDL-C reduction, while triple-negative patients had a markedly high LDL-C elevation rate (up to 50%) in stage IV. Tumor burden-related factors and selected molecular pathology indicators were independently associated with dyslipidemia in a stage-specific manner, and CHD exclusion did not alter the results.
Conclusions
Dyslipidemia is a pervasive and heterogeneous metabolic comorbidity in breast cancer, with distinct stage- and subtype-specific patterns closely linked to tumor burden and molecular biological characteristics. Routine lipid assessment and subtype-tailored metabolic management should be integrated as an essential component into the comprehensive clinical care of breast cancer patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
- Central Laboratory, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
Zitieren
APA
Xin, Z., Qu, H., Li, P., Han, Z., Qu, N., Yu, W., Zhu, X., & Chen, H. (2026). Distribution characteristics and associated factors of dyslipidemia across clinical stages of breast cancer: a retrospective observational study. Frontiers in Global Women's Health, 7. https://doi.org/10.3389/fgwh.2026.1845647
Vancouver
Xin Z, Qu H, Li P, Han Z, Qu N, Yu W, et al. Distribution characteristics and associated factors of dyslipidemia across clinical stages of breast cancer: a retrospective observational study. Frontiers in Global Women's Health. 2026;7. doi:10.3389/fgwh.2026.1845647
BibTeX
@article{Xin2026,
author = {Xin, Zechang and Qu, Hui and Li, Pisong and Han, Zhongbin and Qu, Ningxin and Yu, Weiting and Zhu, Xiaoyu and Chen, Hongshen},
title = {Distribution characteristics and associated factors of dyslipidemia across clinical stages of breast cancer: a retrospective observational study},
journal = {Frontiers in Global Women's Health},
year = {2026},
volume = {7},
doi = {10.3389/fgwh.2026.1845647}
}
EUVIMED